Skip to main content
. 2019 Feb 20;8(8):1062–1072. doi: 10.1002/cpdd.666

Figure 1.

Figure 1

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient disposition in study NCT02720692. IV indicates intravenous. *All treated subjects were to complete a final safety assessment by telephone 28 days following their last study dose; 8 subjects allocated to meloxicam IV 30 mg, and 3 subjects allocated to placebo were lost to follow‐up.